Remarkably, the glyco-engineered anti-PD-L1 induced enhanced CD8 T cell activation in a mixed leukocyte reaction (MLR) determined by expression of activation markers, proliferation, and cytotoxicity against cancer cells, suggesting an improved therapeutic benefit. The gene discussed is CD8A; the disease is cancer.